Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
3 hedge funds and large institutions have $5.52M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
19% more capital invested
Capital invested by funds: $4.66M → $5.52M (+$866K)
0% more funds holding
Funds holding: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCI
Jet Capital Investors
New York
|
+$200K |
Top Sellers
BMY.RT Hedge Fund Activity: Q3 2022 in Review
3 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q3 2022, worth a combined $5.52M — up 19% from $4.66M a quarter earlier.
Fund positioning in BMY.RT was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Jet Capital Investors, adding an estimated $200K.
- 3 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $5.52M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q3 2022, up 19% quarter-over-quarter.
- 0 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q3 2022 and 0 closed out.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q3 2022 was Jet Capital Investors, an estimated $200K added.
Based on aggregated 13F filings for Q3 2022.